碳酸锂合并喹硫平治疗双相障碍抑郁发作的疗效和安全性研究(1)
 |
| 第1页 |
参见附件。
[摘要] 目的 探讨碳酸锂合并喹硫平对双相障碍抑郁发作患者的疗效和安全性。 方法 共入组67例双相障碍患者接受为期8周的开放性治疗，将所有入组患者随机分为两组，研究组(37例)采用碳酸锂合并喹硫平治疗，对照组(30例)单用碳酸锂，在基线期，第1、2、4、8周末采用汉密顿抑郁量表(hamilton depression scale，HAMD-17)评定疗效，采用治疗副反应量表(treatment emergent symptom scale，TESS)评定不良反应。 结果 基线期两组HAMD-17评分差异无统计学意义(P > 0.05)，研究组和对照组各完成研究31例和25例。在治疗后第2、4周研究组比对照组HAMD-17评分下降更明显，差异均有高度统计学意义(均P < 0.01)，在治疗第8周后研究组与对照组HAMD-17评分比较差异无统计学意义(P > 0.05)。两组主要不良反应比较差异无统计学意义(P > 0.05)。 结论 碳酸锂合并喹硫平较单用碳酸锂治疗双相障碍抑郁发作起效更快，不良反应相当，最终总体疗效相当。
[关键词] 双相抑郁；碳酸锂；喹硫平；疗效；安全性
[中图分类号] R749.4 [文献标识码] A [文章编号] 1673-7210(2012)01(b)-086-03
Study of efficacy and safety of Lithium Carbonate combined with Quetiapine in the treatment of bipolar depression
JIANG Yulong1 WU Zhiguo2 SU Yousong2 YI Zhenghui2 WANG Zucheng2 LU Weihong2▲
1.The Mental Health Center of Minhang District, Shanghai 201112, China; 2.The Mental Health Center Affiliated to School of Medicine of Shanghai Jiaotong University, Shanghai 200030, China
[Abstract] Objective To investigate the clinical efficacy and safety of Lithium Carbonate combined with Quetiapine in the treatment of bipolar depression. Methods 67 outpatients with bipolar depression were chosen and taken open treatment for 8 weeks. All patients were randomly divided into two groups. The study group (37 cases) was given Lithium Carbonate combined with Quetiapine, and the control group (30 cases) was given Lithium Carbonate only. The efficacy and adverse reactions at baseline, end of 1st, 2nd, 4th, and 8th week after the treatment were assessed by hamilton depression scale (HAMD-17) and treatment emergent symptom scale (TESS) respectively. Results There were 31 and 25 patients respectively in study group and control group finishing the study. At the baseline, the difference of HAMD-17 scores between research group and control group was no significant (P > 0.05). At the end of 2nd, 4th week after treatment, the HAMD-17 scores in the study group were decreased more significantly than the control group (all P < 0.01). At the end of 8th week, there was no significant difference of HAMD-17 scores between the two groups (P > 0.05). There were no significant differences of adverse reactions between the two groups (P > 0 ......
您现在查看是摘要介绍页，详见PDF附件(2534kb)。